The stock of Vanda Pharmaceuticals Inc (VNDA) has gone up by 4.12% for the week, with a -2.04% drop in the past month and a 1.05% rise in the past quarter. The volatility ratio for the week is 3.64%, and the volatility levels for the past 30 days are 3.89% for VNDA. The simple moving average for the last 20 days is -0.55% for VNDA stock, with a simple moving average of -4.49% for the last 200 days.
Is It Worth Investing in Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Right Now?
The 36-month beta value for VNDA is also noteworthy at 0.77. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VNDA is 55.22M, and at present, short sellers hold a 5.60% of that float. The average trading volume of VNDA on December 20, 2024 was 658.43K shares.
VNDA) stock’s latest price update
Vanda Pharmaceuticals Inc (NASDAQ: VNDA)’s stock price has increased by 3.67 compared to its previous closing price of 4.63. However, the company has seen a 4.12% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-20 that WASHINGTON, Dec. 20, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy that is estimated to affect 1 in 2000 Americans.1 PV is a chronic myeloproliferative disorder characterized by aberrant hematopoiesis of myeloid lineage with exuberant red cell production and increased release of pro-inflammatory cytokines. More than 95% of PV patients harbor the JAK2 V617F gain-of-function mutation leading to aberrant JAK2 production.2 Inhibiting JAK2 acts to suppress hematopoiesis, consequently reducing red blood cell, neutrophil, platelet, and lymphocyte production.
Analysts’ Opinion of VNDA
Many brokerage firms have already submitted their reports for VNDA stocks, with H.C. Wainwright repeating the rating for VNDA by listing it as a “Buy.” The predicted price for VNDA in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on October 31, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VNDA reach a price target of $11. The rating they have provided for VNDA stocks is “Overweight” according to the report published on July 11th, 2024.
Jefferies gave a rating of “Hold” to VNDA, setting the target price at $12 in the report published on February 25th of the previous year.
VNDA Trading at -1.02% from the 50-Day Moving Average
After a stumble in the market that brought VNDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.89% of loss for the given period.
Volatility was left at 3.89%, however, over the last 30 days, the volatility rate increased by 3.64%, as shares sank -4.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.26% upper at present.
During the last 5 trading sessions, VNDA rose by +2.60%, which changed the moving average for the period of 200-days by +23.82% in comparison to the 20-day moving average, which settled at $4.82. In addition, Vanda Pharmaceuticals Inc saw 13.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VNDA starting from Mitchell Stephen Ray, who sale 5,000 shares at the price of $5.17 back on Nov 14 ’24. After this action, Mitchell Stephen Ray now owns 44,857 shares of Vanda Pharmaceuticals Inc, valued at $25,863 using the latest closing price.
Mitchell Stephen Ray, the Director of Vanda Pharmaceuticals Inc, proposed sale 5,000 shares at $5.40 during a trade that took place back on Nov 14 ’24, which means that Mitchell Stephen Ray is holding shares at $27,000 based on the most recent closing price.
Stock Fundamentals for VNDA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.92 for the gross margin
The net margin for Vanda Pharmaceuticals Inc stands at -0.09. The total capital return value is set at -0.07. Equity return is now at value -3.02, with -2.55 for asset returns.
Currently, EBITDA for the company is -10.94 million with net debt to EBITDA at 3.07. When we switch over and look at the enterprise to sales, we see a ratio of 0.98. The receivables turnover for the company is 4.46for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.85.
Conclusion
In summary, Vanda Pharmaceuticals Inc (VNDA) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
